Study on the Mechanism of lcn2 in Obesity

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04573998

Enrollment

500

Registered

2020-10-05

Start date

2016-07-01

Completion date

2024-05-30

Last updated

2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity; Endocrine

Keywords

obesity, lcn2

Brief summary

Obesity is now becoming a worldwide serious problem. Obesity is associated with a spectrum of severe diseases, including diabetes, cardiovascular diseases, and cancers. Lipocalin 2 (LCN2), also known as neutrophil gelatinase associated lipocalin (NGAL), is a member of the lipocalin family. Due to its upregulated expression in infection, LCN2 is originally considered to be a key regulator of immune response. Subsequent investigations revealed that LCN2 is expressed in many tissues and is related to a variety of diseases, including obesity. LCN2 was reported to be increased in obesity individuals. Thus, the investigators decide to investigate the relationship between LCN2 and obesity.

Interventions

PROCEDURELSG

bariatric surgery

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1\) age ranged from 16-65 years old, 2) BMI over 37.5kg/m2, or BMI over 32.5kg/m2 with diabetes which meets the recommended cut off bariatric surgery of the Guidelines for surgical treatment of obesity accompanied with or without type 2 diabetes in China.

Exclusion criteria

1\) secondary cause of obesity such as hypothalamic obesity, Cushing syndrome, and hypophysis dysfunction, etc.,2)pregnancy or location, 3) contraindications for laparoscopic surgery, such as gastrointestinal diseases of intra-abdominal infection, adhesion, etc., 4) severe heart, liver and kidney dysfunction, 5) organic and systemic diseases intolerant of surgery.

Design outcomes

Primary

Measure	Time frame	Description
LCN2 level	2019-2024	Lipocalin 2 level
meet the criteria of metabolism in the 2017 Chinese guideline	2019-2024	Abdominal obesity (or central obesity), male abdominal circumference ≥90cm, female abdominal circumference ≥85cm;

Secondary

Measure	Time frame	Description
FBG	2019-2024	patients with fasting blood glucose 6.1mmol/l or more
PBG	2019-2024	patients with 2 hour blood glucose 7.8mmol/l or more

Countries

China

Contacts

Primary ContactLe Bu, Dr.

geyingjun@hotmail.com(86)021-66301004

Backup ContactShen Qu, Dr.

qushencn@hotmail.com(86)021-66301004

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026